Development of a putative Zn²⁺-chelating but highly selective MMP-13 inhibitor

Area of Science:

• Medicinal Chemistry
• Enzyme Inhibitor Development
• Osteoarthritis Therapeutics

Background:

• Matrix metalloproteinase-13 (MMP-13) plays a key role in cartilage degradation in osteoarthritis.
• Developing selective MMP-13 inhibitors is challenging due to potential off-target effects and lack of selectivity within the MMP family.
• Optimizing interactions near the enzyme's active site, particularly the Zn2+ binding site, is crucial for potent inhibition.

Purpose of the Study:

• To design and synthesize novel MMP-13 inhibitors with improved selectivity and potency.
• To investigate the structure-activity relationship (SAR) of oxetane-containing compounds targeting MMP-13.
• To evaluate the in vitro and in vivo efficacy and pharmacokinetic properties of a lead compound for osteoarthritis.

Main Methods:

• Structure-Activity Relationship (SAR) studies based on a known MMP-13 inhibitor.
• Synthesis of novel oxetane-containing compounds, including compound 32.
• In vitro enzymatic assays to determine MMP-13 inhibition (IC50) and selectivity across the MMP family.
• Molecular docking studies to elucidate the binding mode of the oxetane moiety.
• In vivo pharmacokinetic studies in a rat knee joint model.

Main Results:

• Compound 32, featuring an oxetane ring, demonstrated potent MMP-13 inhibition (IC50 = 42 nM) and complete inhibition of collagenolysis in vitro.
• Compound 32 exhibited an excellent selectivity profile among MMP family members, a rare finding for MMP-13 inhibitors with metal-chelating potential.
• Docking studies suggested the oxetane ring chelates the Zn2+ ion, with selectivity attributed to combined interactions with the S1' loop.
• In vivo studies showed compound 32 achieved a concentration of 1.97 μM in rat synovial fluid.

Conclusions:

• The oxetane-containing compound 32 represents a highly selective and potent MMP-13 inhibitor.
• The observed selectivity is likely due to a combination of oxetane chelation and interactions within the S1' loop.
• Compound 32's favorable pharmacokinetic profile in synovial fluid makes it a promising lead candidate for further development in osteoarthritis treatment.